Document And Entity Information
Document Type
Document Type
Document Quarterly Report
Document Transition Report
Document Period End Date
Document Period End Date
Securities Act File Number
Entity Registrant Name
Entity Registrant Name
Entity Incorporation, State or Country Code
Entity Tax Identification Number
Entity Address, Address Line One
Entity Address, City or Town
Entity Address, State or Province
Entity Address, Postal Zip Code
City Area Code
Local Phone Number
Title of 12(b) Security
Trading Symbol
Security Exchange Name
Entity Interactive Data Current
Entity Filer Category
Entity Filer Category
Entity Current Reporting Status
Entity Current Reporting Status
Entity Shell Company
Entity Shell Company
Entity Small Business
Entity Small Business
Entity Emerging Growth Company
Entity Emerging Growth Company
Entity Common Stock, Shares Outstanding
Entity Common Stock, Shares Outstanding
Entity Central Index Key
Entity Central Index Key
Current Fiscal Year End Date
Current Fiscal Year End Date
Document Fiscal Year Focus
Document Fiscal Year Focus
Document Fiscal Period Focus
Document Fiscal Period Focus
Amendment Flag
Amendment Flag
CONDENSED CONSOLIDATED BALANCE SHEETS
Statement [Table]
Statement [Table]
Related and Nonrelated Parties [Axis]
Related and Nonrelated Parties [Domain]
Related Party [Member]
Related party
Nonrelated Party [Member]
Non-related party
Statement [Line Items]
Statement [Line Items]
Assets [Abstract]
ASSETS
Assets, Current [Abstract]
CURRENT ASSETS:
Cash and Cash Equivalents, at Carrying Value
Cash and cash equivalents
Accounts Receivable, after Allowance for Credit Loss, Current
Accounts receivable
Unbilled Receivables, Current
Unbilled receivables - related party
Unbilled receivables
Prepaid Expense, Current
Prepaid expenses
Income Taxes Receivable
Tax incentive receivable
Other Assets, Current
Other current assets
Assets, Current
Total Current Assets
Property, Plant and Equipment, Net.
Property, plant and equipment, net
Intangible Assets, Net (Excluding Goodwill)
Intangible assets, net
Restricted Cash, Noncurrent
Restricted cash
Other Assets, Noncurrent
Other assets
Long-Term Investments
Total equity method and other investments - Carrying Value
Equity method and other investments
Operating Lease, Right-of-Use Asset
Right-of-use assets - operating leases, net
Right-of-use assets
Finance Lease, Right-of-Use Asset, after Accumulated Amortization
Right-of-use assets
Right-of-use assets - finance leases, net
Assets
TOTAL ASSETS
Liabilities and Equity [Abstract]
LIABILITIES AND SHAREHOLDERS' EQUITY
Liabilities, Current [Abstract]
CURRENT LIABILITIES:
Accounts Payable, Current
Accounts payable
Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Excluding income taxes, used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
Accrued Liabilities, Excluding Income Taxes, Current
Accrued expenses
Operating Lease, Liability, Current
Lease obligations - operating leases, current
Finance Lease, Liability, Current
Lease obligations - finance leases, current
Contract with Customer, Liability, Current
Deferred revenue
Notes Payable, Current
Note payable, net, current
Outstanding debt obligation
Accrued Income Taxes, Current
Corporate tax liability
Other Liabilities, Current
Other current liabilities
Liabilities, Current
Total Current Liabilities
Deferred Income, Noncurrent
Deferred revenue - related party
Operating Lease, Liability, Noncurrent
Lease obligations - operating leases
Finance Lease, Liability, Noncurrent
Lease obligations - finance leases
Asset Retirement Obligation
Asset retirement obligations at end of period
Asset retirement obligations at beginning of period
Asset retirement obligations
Notes Payable, Noncurrent
Note payable, net
Liabilities
TOTAL LIABILITIES
Commitments and Contingencies.
COMMITMENTS AND CONTINGENCIES (Note 13)
Equity, Attributable to Parent [Abstract]
SHAREHOLDERS' EQUITY (DEFICIT):
Common Stock, Value, Issued
Ordinary Shares, $0.00003881 par value, 1,288,327,750 authorized, 94,188,118 and 81,120,931 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively
Additional Paid in Capital
Capital in excess of par value
Treasury Stock, Common, Value
Treasury shares
Accumulated Other Comprehensive Income (Loss), Net of Tax
Accumulated other comprehensive gain
Retained Earnings (Accumulated Deficit)
Accumulated deficit
Accumulated deficit
Equity, Attributable to Noncontrolling Interest
Non-controlling interest
Equity, Including Portion Attributable to Noncontrolling Interest
Ending Equity Balance
Beginning Equity Balance
Total Shareholders' Equity (Deficit)
Liabilities and Equity
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY (DEFICIT)
Common Stock, Par or Stated Value Per Share
Common stock, par value
Common Stock, Shares Authorized
Common stock, shares authorized
Common Stock, Shares, Issued
Common stock, shares issued
Common Stock, Shares, Outstanding
Ending Equity Balance (shares)
Beginning Equity Balance (shares)
Common stock, shares outstanding
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS)
Statement of Operations
Product and Service [Axis]
Product and Service [Domain]
Service [Member]
Service revenue
Revenue from related parties earned for services rendered.
Related Party Service Revenue [Member]
Service revenue - related party
Service revenue
Represents the information pertaining to license revenue from related party.
Related Party License Revenue [Member]
License revenue
License revenue - related party
Revenues
Total revenue
Operating Expenses [Abstract]
Operating expenses:
Cost of Revenue
Cost of service revenue
General and Administrative Expense
General and administrative expense
General and administrative
Research and Development Expense
Research and development expense
Research and development
Operating Expenses
Total operating expenses
Total operating expenses
Operating Income (Loss)
Income (loss) from operations
Other Nonoperating Income (Expense) [Abstract]
Other non-operating income (expense):
Gain (Loss), Foreign Currency Transaction, before Tax
Foreign currency loss (gain)
Foreign currency (loss) gain
Investment Income, Interest
Interest income
Interest Expense, Operating and Nonoperating
Interest expense
Unrealized Gain (Loss) on Derivatives
Loss on derivative liability
Loss on derivative liability
Income (Loss) from Equity Method Investments
Loss on equity method investee
Income Tax Expense (Benefit)
Income tax expense
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest
Net income (loss)
Net income (loss)
Net income (loss)
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest [Abstract]
Net income (loss) attributed to:
Net Income (Loss) Attributable to Noncontrolling Interest
Net loss attributed to non-controlling interest
Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]
Other comprehensive gain (loss):
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax
Foreign currency translation gain (loss) attributed to shareholders
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Noncontrolling Interest
Foreign currency translation loss attributed to non-controlling interest
Comprehensive Income (Loss), Net of Tax, Attributable to Parent
Comprehensive income (loss)
Earnings Per Share, Basic
Basic net income (loss) per ordinary share
Earnings Per Share, Diluted
Diluted net income (loss) per ordinary share
Weighted Average Number of Shares Outstanding, Basic
Weighted-average number of ordinary shares outstanding, basic
Weighted Average Number of Shares Outstanding, Diluted
Weighted-average number of ordinary shares outstanding, diluted
Weighted average ordinary shares outstanding - diluted
CONDENSED CONSOLIDATED STATEMENT OF SHAREHOLDERS' EQUITY
Equity Components [Axis]
Equity Component [Domain]
Common Stock [Member]
Ordinary Shares
Additional Paid-in Capital [Member]
Capital in Excess of Par Value
Treasury Stock, Common [Member]
Treasury Shares
AOCI Attributable to Parent [Member]
Accumulated Other Comprehensive Gain
Retained Earnings [Member]
Accumulated Deficit
Noncontrolling Interest [Member]
Non-Controlling Interest
Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture
Share-based compensation activity
Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture
Share-based compensation activity (shares)
Stock Issued During Period, Value, New Issues
Issuance of ordinary shares in at-the-market offering
Stock Issued During Period, Shares, New Issues
Shares issued
Issuance of ordinary shares in at-the-market offering (shares)
Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs
Issuance costs in connection with ordinary shares
Treasury Stock, Value, Acquired, Cost Method
Repurchase of treasury shares
Treasury Stock, Shares, Acquired
Repurchase of treasury shares (shares)
Stock Issued During Period, Value, Acquisitions
Issuance of ordinary shares in connection with license agreement
Stock Issued During Period, Shares, Acquisitions
Issuance of ordinary shares in connection with license agreement (shares)
Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation
Taxes withheld on issuance of share-based awards
Taxes withheld on issuance of share-based awards
Value of stock issued pursuant to a registered offering.
Issuance of shares in connection with registered offering
Issuance of shares in connection with registered offering
Number of shares of stock issued during the period pursuant to registered offerings.
Issuance of shares in connection with registered offering (shares)
Noncontrolling Interest, Increase from Subsidiary Equity Issuance
Contributions from non-controlling interest
Noncontrolling Interest, Increase from Sale of Parent Equity Interest
Sale of non-controlling interest
Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock in private placement offerings.
Issuance costs in connection with private placement offering
Issuance costs in connection with private placement
Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income.
Comprehensive Income (Loss), Net of Tax, Other
Other comprehensive gain (loss)
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
Net Cash Provided by (Used in) Operating Activities [Abstract]
Cash flows from operating activities:
Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]
Adjustments to reconcile net income (loss) to net cash used in operating activities:
Share-Based Payment Arrangement, Noncash Expense
Share-based compensation
Share-based compensation expense
Depreciation, Depletion and Amortization
Depreciation and amortization
Amount of change in right of use assets.
Change In Right Of Use Assets
Change in right-of-use assets
Gain (Loss) on Termination of Lease
Gain on termination of lease liabilities
Gain (Loss) on Disposition of Property Plant Equipment
Loss (gain) on disposal of equipment, furniture and fixtures
Income (Loss) from Equity Method Investments, Net of Dividends or Distributions
Undistributed losses of equity method investee
Asset Retirement Obligation, Accretion Expense
Amortization of interest on asset retirement obligations
Amortization of Debt Discount (Premium)
Amortization of debt discount
Amount of revenue included in net income that result in no cash inflow (outflow).
Noncash Revenue received
Non-cash consideration received from related party - revenue arrangement
Amount of addition (reduction) to the amount of acquired in-process research and development assets.
Increase Decrease in Acquired In-process Research and Development Assets
Acquired in-process research and development
Increase (Decrease) in Operating Assets [Abstract]
(Increase) decrease in operating assets:
Increase (Decrease) in Accounts Receivable
Accounts receivable
Increase (Decrease) in Accounts Receivable, Related Parties
Accounts receivable - related party
The increase (decrease) during the reporting period in the amount due to the reporting entity for services rendered and products shipped, but not yet billed to the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management, an entity and its principal owners, management, member of their immediate families, affiliates, or other parties with the ability to exert significant influence.
Increase (Decrease) in Unbilled Receivable, Related Parties
Unbilled receivables - related party
Increase (Decrease) in Contract with Customer, Asset
Contract assets - related party
Increase (Decrease) in Prepaid Expense
Prepaid expenses
Increase (Decrease) in Other Receivables
Tax incentive receivable
Increase (Decrease) in Other Current Assets
Other current assets
Increase (Decrease) in Other Noncurrent Assets
Other assets, net
Increase (Decrease) in Operating Liabilities [Abstract]
Increase (decrease) in operating liabilities:
Increase (Decrease) in Accounts Payable
Accounts payable
Increase (Decrease) in Accrued Liabilities
Accrued expenses
Amount of increase (decrease) in obligation for lease.
Increase (Decrease) in Lease Liabilities
Lease liabilities
Increase (Decrease) in Income Taxes Payable, Net of Income Taxes Receivable
Corporate tax liability
Increase (Decrease) in Other Current Liabilities
Other current liabilities
Increase (Decrease) in Contract with Customer, Liability
Deferred revenue
The increase (decrease) during the reporting period in the obligations to transfer good or service to customer for which consideration has been received or is receivable from the following types of related parties: a parent company and its subsidiaries, subsidiaries of a common parent, an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management, an entity and its principal owners, management, or member of their immediate families, affiliates, or other parties with the ability to exert significant influence.
Increase (Decrease) in Contract With Customer Liability, Related parties
Deferred revenue - related party
Net Cash Provided by (Used in) Operating Activities
Cash flows from operations
Net cash used in operating activities
Net Cash Provided by (Used in) Investing Activities [Abstract]
Cash flows from investing activities:
Payments to Acquire Property, Plant, and Equipment
Purchase of property, plant and equipment
Payments to Acquire in Process Research and Development
Acquisition of in-process research and development assets
Proceeds from Divestiture of Interest in Consolidated Subsidiaries
Proceeds from sale of non-controlling interest
Proceeds from Sale of Property, Plant, and Equipment
Proceeds from sale of equipment, furniture and fixtures
Net Cash Provided by (Used in) Investing Activities
Net cash used in investing activities
Net Cash Provided by (Used in) Financing Activities [Abstract]
Cash flows from financing activities:
Proceeds from Stock Options Exercised
Exercise of share options
Payment, Tax Withholding, Share-Based Payment Arrangement
Payments of withholdings on shares withheld for income taxes
Finance Lease, Principal Payments
Payments on lease obligations - financing leases
Proceeds from Issuance of Common Stock
Proceeds from the issuance of ordinary shares
Aggregate offering price authorized through at-market offerings
Payments of Stock Issuance Costs
Issuance costs in connection with ordinary shares
Payments for Repurchase of Common Stock
Payment for treasury shares
Proceeds from Noncontrolling Interests
Contributions from non-controlling interest
Repayments of Notes Payable
Payment of notes payable
Repayment of outstanding principle
Proceeds from Issuance of Long-Term Debt
Proceeds from royalty notes payable
Net Cash Provided by (Used in) Financing Activities
Net cash provided by financing activities
Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect
Net increase (decrease) in cash, cash equivalents and restricted cash
Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations
Effect of exchange rate changes on cash, cash equivalents and restricted cash
Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents
Cash, cash equivalents and restricted cash at end of the period
Cash, cash equivalents and restricted cash at beginning of the period
Total cash, cash equivalents and restricted cash in the condensed consolidated statement of cash flows
Cash, cash equivalents
Noncash Investing and Financing Items [Abstract]
Supplemental disclosure of non-cash transactions:
Fair Value of Assets Acquired
Non-cash contribution for acquisition of in-process research and development
Stock Issued
Issuance of shares in connection with a license agreement
Asset Acquisition, Consideration Transferred, Contingent Consideration
Fixed asset acquisitions included in accounts payable and accrued expenses
Future contingent consideration
The amount of issuance costs that were incurred during a noncash or partial noncash transaction.
Issuance Costs Incurred During Noncash or Partial Noncash Transaction
Issuance costs in connection with sale of ordinary shares in accounts payable and accrued expenses at end of period
Supplemental Cash Flow Information [Abstract]
Supplemental disclosure of cash flow information:
Interest Paid, Excluding Capitalized Interest, Operating Activities
Cash paid for interest
Organization and Basis of Presentation
Business Description and Basis of Presentation [Text Block]
Organization and Basis of Presentation
Summary of Significant Accounting Policies and Recent Accounting Pronouncements
Significant Accounting Policies [Text Block]
Summary of Significant Accounting Policies and Recent Accounting Pronouncements
Equity Method and Other Investments
Equity Method Investments and Joint Ventures Disclosure [Text Block]
Equity Method and Other Investments
Accrued Expenses
Accounts Payable and Accrued Liabilities Disclosure [Text Block]
Accrued Expenses
No definition available.
Financial Instruments
Financial Instruments Disclosure [Text Block]
Financial Instruments
Share-Based Compensation
Share-Based Payment Arrangement [Text Block]
Share-Based Compensation
Ordinary Shares
Equity [Text Block]
Ordinary Shares
Earnings Per Share
Earnings Per Share [Text Block]
Earnings Per Share
Income Taxes
Income Tax Disclosure [Text Block]
Income Taxes
Related-Party Transactions
Related Party Transactions Disclosure [Text Block]
Related-Party Transactions
Leases
Lessee, Operating Leases [Text Block]
Leases
Debt Financing
Debt Disclosure [Text Block]
Debt Financing
Commitments and Contingencies
Commitments Disclosure [Text Block]
Commitments and Contingencies
Consolidation, Policy [Policy Text Block]
Consolidation
Use of Estimates, Policy [Policy Text Block]
Use of Estimates
Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]
Restricted Cash
Fair Value Measurement, Policy [Policy Text Block]
Fair Value Measurements
Asset Retirement Obligation [Policy Text Block]
Asset Retirement Obligations
Disclosure of accounting policy for IDA Ireland Grants.
Schedule of Ireland Grants [Policy Text Block]
IDA Ireland Grant
Revenue [Policy Text Block]
Revenue Recognition
Research and Development Expense, Policy [Policy Text Block]
Research and Development
Stockholders' Equity, Policy [Policy Text Block]
Treasury Shares
Earnings Per Share, Policy [Policy Text Block]
Net Income (Loss) per Ordinary Share
Segment Reporting, Policy [Policy Text Block]
Segment Information
Disclosure of accounting policy for non controlling interests.
Non controlling Interest Policy [Policy Text Block]
Non-Controlling Interests
Disclosure of accounting policy pertaining to new accounting pronouncements adopted.
Recent Accounting Pronouncements Adopted [Policy Text Block]
Recent Accounting Pronouncements Adopted
New Accounting Pronouncements, Policy [Policy Text Block]
Recent Accounting Pronouncements Not Yet Adopted
Restrictions on Cash and Cash Equivalents [Table Text Block]
Schedule of Restricted Cash
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]
Schedule of Financial Assets and Liabilities Measured at Fair Value
Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]
Schedule of estimate fair value
Schedule of Change in Asset Retirement Obligation [Table Text Block]
Schedule of Change in Asset Retirement Obligations
Schedule of Segment Reporting Information, by Segment [Table Text Block]
Schedule of Net income (loss) for the Segment
Long-Lived Assets by Geographic Areas [Table Text Block]
Schedule of Long-lived Assets by Geographical Area
Equity Method Investments [Table Text Block]
Schedule of Equity Method and Other Investments
Schedule of Accrued Liabilities [Table Text Block]
Schedule of Accrued Expenses
Tabular disclosure of financial instruments held by the entity for its own account for trading or investment purposes.
Schedule of Financial Instruments [Table Text Block]
Schedule of financial instruments
Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]
Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]
Restricted Stock Units (RSUs) [Member]
Restricted share units
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-Based Payment Arrangement, Option, Activity [Table Text Block]
Schedule of Share Option Activity
Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]
Schedule of Inputs Used in Determining Fair Value of Share Options
Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]
Schedule of Restricted Share Unit (RSU) Activity
Share-Based Payment Arrangement, Cost by Plan [Table Text Block]
Schedule of Share-Based Compensation Expense
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]
Schedule of Basic and Diluted Net Loss per Share
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]
Schedule of Securities Excluded from Computation of Diluted Net Loss per Share
Related Party Transaction [Table]
Schedule of Related Party Transactions, by Related Party [Table]
Related Party Transaction [Axis]
Related Party Transaction [Domain]
Asset purchase agreement as defined by the Company.
Asset Purchase Agreement [Member]
Asset Purchase Agreement
Related Party Transaction [Line Items]
Related-Party Transactions
Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]
Summary of the deferred revenue
Lease, Cost [Table Text Block]
Schedule of Components of Lease Cost
Tabular disclosure of long-lived, depreciable assets that are subject to a lease meeting the criteria for capitalization and are used in the normal conduct of business to produce goods and services. Examples may include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.
Schedule of Amounts Reported in the Consolidated Balance Sheets for Leases [Table Text Block]
Schedule of Amounts Reported in the Consolidated Balance Sheets for Leases
Schedule of Components of Leveraged Lease Investments [Table Text Block]
Schedule of Other Information Related to Leases
Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.
Schedule of Future Minimum Payments Under Non-cancellable Leases [Table Text Block]
Schedule of Future Minimum Payments Under Non-Cancellable Leases
Collaborative Arrangement and Arrangement Other than Collaborative [Table]
Subsequent Event Type [Axis]
Subsequent Event Type [Domain]
Subsequent Event [Member]
Subsequent Event
Statistical Measurement [Axis]
Statistical Measurement [Domain]
Maximum [Member]
Maximum
Counterparty Name [Axis]
Counterparty Name [Domain]
Janssen Pharmaceuticals Inc [Member]
Janssen Pharmaceuticals Inc
Information pertaining to Hologen Limited.
Hologen Limited [Member]
Hologen Limited
Information pertaining to Eli Lilly and Company.
Eli Lilly and Company [Member]
Eli Lilly
Collaborative Arrangement and Arrangement Other than Collaborative [Axis]
Collaborative Arrangement and Arrangement Other than Collaborative [Domain]
Collaborative Arrangement [Member]
Collaboration Agreement
Collaborative transaction with Hologen Limited.
Hologen Transaction Agreement [Member]
Hologen Strategic Agreement
Information pertaining to the collaborative agreement with Eli Lilly and Company.
Eli Lilly and Company Collaboration Agreement [Member]
Eli Lilly Collaboration Agreement
Ownership [Axis]
Ownership [Domain]
Represents the member information pertaining to MeiraGTx Manufacturing Limited.
MeiraGTx Manufacturing Limited [Member]
MeiraGTx Manufacturing Limited
Represents the information pertaining to Reogen limited.
Reogen Limited [Member]
Reogen limited
Reogen
Legal Entity [Axis]
All Entities [Member]
Represents the member information pertaining to MeiraGTx Neuro UK Limited.
MeiraGTx Neuro UK Limited [Member]
MeiraGTx Neuro UK Limited
Asset Acquisition [Axis]
Asset Acquisition [Domain]
Represents the member information pertaining to research, development, manufacture and exploitation of Seller's gene therapy product for the treatment of X-linked retinitis pigmentosa related to mutations in the RPGR gene (the "RPGR Product"), and other related assets.
Research, Development And Other Assets [Member]
Research, Development And Other Assets
Pertaining to JJDC - the investment arm of Johnson & Johnson and owner of Janssen.
JJDC
Investment, Name [Axis]
Investment, Name [Domain]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Represents the total number of clinical programs that have reached late-stage development.
Number of Late Stage Clinical Programs
Number of late stage clinical programs
Represents the total number of manufacturing facilities licensed for Good Manufacturing Practice (GMP) production.
Number of GMP-Licensed Manufacturing Facilities
Number of GMP-Licensed
Represents the minimum duration over which the company has developed its proprietary manufacturing platform process.
Minimum Development Period of Proprietary Manufacturing Platform
Minimum development period of proprietary manufacturing platform
Represents the minimum number of different viral vectors developed and tested, demonstrating leading yield, quality, and commercial readiness.
Minimum Number of Distinct Viral Vectors Utilized
Minimum number of distinct viral vectors utilized
Milestone funding received in collaboration with Hologen Limited.
Milestone funding upfront payment received
Milestone funding upfront payment received
Milestone funding received as additional capital of up to fund the development of the Clinical Programs and the Delivery Device
Milestone funding to provide additional capital
Milestone funding to provide additional capital
Stock issued during period in connection with strategic agreement.
Class A shares of Hologen received in transaction
Class A shares of Hologen received in transaction
Equity Method Investment, Ownership Percentage
Equity ownership in outstanding ordinary shares
Equity Method Investment - Ownership Percentage
Amount of Upfront payment receivable
Upfront Payment Receivable
Upfront payment
The percentage of ownership interest held post collaboration agreement funding.
Expected Ownership Percentage Held Post Collaboration Agreement Funding
Expected ownership percentage held post collaboration agreement funding
Represents the maximum ownership percentage may hold if option is exercised.
Maximum Ownership Percentage May Hold if Option is Exercised
Maximum ownership percentage
Funding received from the Company's collaboration agreement with Janssen Pharmaceuticals for the research, development and commercialization of gene therapies for the treatment of inherited retinal diseases..
Collaboration Agreement Funding Received
Initial funding
Equity Ownership, Excluding Consolidated Entity and Equity Method Investee, Percentage
Ownership interest
Equity Investment - Ownership Percentage
Period over which grantee's right to purchase shares under transaction arrangement is no longer effective, and the company's irrevocable option to repurchase shares becomes effective, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.
Agreement, Sell Or Transfer Of Shares, Notice Period
Number of business days
Maximum contingent funding available under the Company's asset purchase agreement with Janssen Pharmaceuticals.
Contingent funding available
Milestone funding available in other near-term cash consideration upon the achievement of certain development and regulatory approval milestones.
Milestone funding available upon certain development and regulatory approvals
Milestone funding contingent on development and regulatory approval
Payments to Acquire Productive Assets
Upfront cash payment
The amount of sales threshold required to trigger contingent consideration payment.
Sales Threshold required to Trigger Contingent Consideration Payment
Sales threshold payment
The cash inflow during the period from debt and common stock.
Proceeds From Issuance of Debt And Common Stock
Gross proceeds
The amount of milestone payment to be received.
Milestone Payment to be Received
Milestone payment to be received
Fair Value, Recurring and Nonrecurring [Table]
Fair Value Measurements, Recurring and Nonrecurring [Table]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Restricted cash and fair value measurements
Measurement Frequency [Axis]
Measurement Frequency [Domain]
Fair Value, Recurring [Member]
Fair value measurements on recurring basis
Fair Value Hierarchy and NAV [Axis]
Fair Value Hierarchy and NAV [Domain]
Fair Value, Inputs, Level 1 [Member]
Level 1
Significant Observable Inputs (Level 1)
Fair Value, Inputs, Level 3 [Member]
Level 3
Significant Unobservable Inputs (Level 3)
Asset Class [Axis]
Asset Class [Domain]
Cash and Cash Equivalents [Member]
Cash equivalents
Cash and Cash Equivalents, Fair Value Disclosure
Cash equivalents
Fair value of contingent forward contract representing the Company's obligation to issue additional subsidiary shares in exchange for future funding commitments under a collaboration arrangement, classified as an asset or liability based on whether the contract is in a favorable or unfavorable position to the Company.
Contingent Forward Instrument Asset (Liability) Fair Value Disclosure
Contingent forward instrument (Note 5)
Notes Payable, Fair Value Disclosure
Royalty Notes (Note 12)
Derivative Liability, Current
Derivative liability (Note 5)
Derivative liability
Fair value of the equity option liability associated with an option to acquire additional ownership interests in an subsidiary.
Equity Option Liability, Fair Value Disclosure
Equity option instrument (Note 5)
Fair Value, Net Asset (Liability)
Fair value, net asset (liability)
Measurement Input Type [Axis]
Measurement Input Type [Domain]
Measurement Input, Discount Rate [Member]
Discount rate
Measurement Input, Price Volatility [Member]
Expected volatility
Measurement Input, Expected Term [Member]
Expected term
Measurement Input, Risk Free Interest Rate [Member]
Risk-free interest rate
Valuation Approach and Technique [Axis]
Valuation Approach and Technique [Domain]
Valuation Technique, Monte Carlo Pricing Model [Member]
Monte Carlo simulation
Minimum [Member]
Minimum
Value of input used to measure contingent forward asset (liability).
Contingent Forward Asset (Liability) Measurement Input
Contingent forward instrument
Derivative Liability, Measurement Input
Derivative liability
Value of input used to measure equity option liability.
Equity Option Liability, Measurement Input
Equity option instrument
Property, Plant and Equipment [Table]
Property, Plant and Equipment [Line Items]
Asset retirement obligations
Asset Retirement Obligation, Liabilities Settled
Asset retirement obligation liability
Leasehold Improvements, Gross
Leasehold improvements associated with terminated lease
Asset Retirement Obligation, Cash Paid to Settle
Decontamination costs related to ARO
Amount of gain (loss) on termination of lease before expiration of lease term.
Gain on termination of lease liabilities
Gain on termination of lease
Asset Retirement Obligation, Revision of Estimate
Change in estimate
Amortization of interest on asset retirement obligation.
Asset Retirement Obligations, Amortization of Interest
Amortization of interest
Asset Retirement Obligation, Foreign Currency Translation Gain (Loss)
Effects of exchange rate changes
Government Assistance [Table]
Government Assistance, Type [Axis]
Government Assistance, Type [Domain]
Represents information pertaining to IDA Ireland grants for financial assistance.
Grants IDA Ireland [Member]
IDA Ireland Financial Assistance Grants
Represents information pertaining to IDA Ireland grants for employment.
Grants IDA Ireland Employment [Member]
IDA Ireland Employment Grants
Represents information pertaining to IDA Ireland grants for capital expenditures.
Grants IDA Ireland Capital [Member]
IDA Ireland Capital Grants
Government Assistance [Line Items]
IDA Ireland grant
Amount of financial assistance available for each new job created.
Grant amount for job creation
Grant funding for each new job created
Amount of financial assistance available for creation of machinery and equipment that provides opportunities for new jobs.
Grant amount for machinery and equipment
Grant funding available for the creation of machinery and equipment that leads to job creation, expressed as a percent of total cost to produce machinery and equipment.
Grants for machinery and equipment as a percentage of total cost to make
Grant amount for machinery and equipment (percent of actual expenditure)
Represents the aggregate number of jobs created in order to be eligible to receive financial assistance under IDA Ireland grants.
Number of new jobs created to receive Grant funding
Aggregate number of new jobs required to receive grant benefits
Financial assistance duration period, measured from the last date of payment received in IDA Ireland grant funding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.
Financial Assistance Duration From Last Grant Payment
Termination period (from last grant payment)
Financial assistance duration period, measured from the date in which capital investments for eligible machinery and equipment are completed, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.
Financial Assistance Duration From Completion of Capital Investment
Termination period (upon completion of capital investment)
Expenditure requirements on eligible machinery and equipment in order to receive maximum benefits from IDA Ireland financial assistance grants.
Expenditure requirement for grant funding on eligible machinery and equipment
Expenditure requirement on eligible machinery and equipment
Period benchmark in which the Company may be held to repay a portion of capital grants if a job for which the Company received employment grant funding remains vacant, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.
Period of job vacancy before grant funding becomes repayable
Vacant job duration prompting repayment of grant funding
Schedule of Segment Reporting Information, by Segment [Table]
Segments [Axis]
Segments [Domain]
Represents the information pertaining to single reportable segment.
Single Reportable Segment [Member]
Single reportable segment
Segment Reporting Information [Line Items]
Number of Reportable Segments
Number of reportable segments
Number of Operating Segments
Number of operating segments
Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.
Service revenue from related parties
Service revenue - related party
The segment total of research and development expenses.
Segment general and administrative expenses
General and administrative
Amount of expense for clinical trials for Botaretigene Sparoparvovec drug substances.
Clinical Programs Drug Product 1
Botaretigene sparoparvovec
Amount of expense for clinical trials for AAV-hAQP1 drug substances.
Clinical Programs Drug Product 2
AAV-hAQP1
Amount of expense for clinical trials for AAV-GAD drug substances.
Clinical Programs Drug Product 4
AAV-GAD
Amount of expense for research and development pertaining to clinical trials for drug substances.
Research and development clinical trials
Other ocular diseases
Amount of expense for research and development pertaining to manufacturing of drug substances.
Research and development Manufacturing
Manufacturing
Amount of expense for pre-clinical research relating to gene regulation.
Pre-clinical research Gene Regulation
Gene regulation
Amount of expense for pre-clinical research relating to neurodegenerative diseases.
Pre-clinical research Neurodegenerative Diseases
Neurodegenerative diseases
Amount of expense for pre-clinical research relating to preclinical ocular diseases.
Pre-clinical research Preclinical Ocular Diseases
Preclinical ocular diseases
Amount of expense for research and development classified as other.
Research and development other
Other research and development
Other segment items of income (expense).
Other segment items income statement
Other segment items
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Segment net income (loss)
Segment net income (loss)
Schedule of Revenues from External Customers and Long-Lived Assets [Table]
Geographical [Axis]
Geographical [Domain]
UNITED STATES
United States
UNITED KINGDOM
United Kingdom
European Union [Member]
European Union
Revenues from External Customers and Long-Lived Assets [Line Items]
Long-lived assets by geographical area
Long-Lived Assets
Non-current assets
Equity Method Investment [Table]
Represents information pertaining to Visiogene LLC.
Visiogene LLC
Visiogene LLC
Represents information pertaining to equity method investments other than Visogene LLC.
Other Investments
Other
Schedule of Equity Method Investments [Line Items]
Equity Method and Other Investments
Equity Securities without Readily Determinable Fair Value, Amount
Carrying Value
Carrying amount
Amount of investment in equity security without readily determinable fair value and are measured using the cost basis method.
Equity Securities without Readily Determinable Fair Value, Amount, Cost Basis
Cost Basis
Total cost basis of long-term investments, including equity method investments and equity investments.
Long Term Investments Cost Basis
Total equity method and other investments - Cost Basis
Equity Method Investments
Carrying amount of investment
Number of equity securities acquired as part of a strategic collaboration.
Equity Securities, Acquired Through Strategic Collaboration
Aggregate ordinary shares acquired
Equity Method Investment, Nonconsolidated Investee [Axis]
Equity Method Investment, Nonconsolidated Investee [Domain]
Other Income
Other income
Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest
Net loss
Accrued Liabilities Accrued Compensation And Benefits
Accrued Liabilities Accrued Compensation And Benefits
Compensation and benefits
Accrued Professional Fees, Current
Professional fees
Accrued Research And Development
Accrued Research And Development
Research and development
Accrued Liabilities Accrued Manufacturing Costs Expense.
Accrued Liabilities Accrued Manufacturing Costs Expense
Manufacturing costs
Accrued Consulting Expenses
Accrued Consulting Expenses
Consulting
Accrued Clinical Trial Costs
Accrued Clinical Trial Costs
Clinical trial costs
Deposit Liabilities, Accrued Interest
Interest on Tranche 1 Notes
Other Accrued Liabilities, Current
Other
Accrued Liabilities, Current
Accrued expenses
Carrying amount of contingent forward contract representing the Company's obligation to issue additional subsidiary shares in exchange for future funding commitments under a collaboration arrangement, classified as an asset or liability based on whether the contract is in a favorable or unfavorable position to the Company.
Contingent Forward Instrument, Asset (Liability)
Contingent forward instrument
Derivative Liability, Current, Statement of Financial Position [Extensible Enumeration]
Carrying amount of liability associated with an option to acquire additional ownership interests in an subsidiary, classified as current.
Equity Option Liability, Current
Equity option liability
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]
Number of Options
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number
Number of options, Ending balance
Number of options, Beginning balance
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross
Number of options, Granted
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period
Number of options, Exercised
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period
Number of options, Forfeited
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period
Number of options, Expired
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]
Weighted-Average Exercise Price
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price
Weighted-average exercise price, Ending balance
Weighted-average exercise price, Beginning balance
Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price
Weighted-average exercise price, Granted
Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price
Weighted-average exercise price, Exercised
Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price
Weighted-average exercise price, Forfeited
Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price
Weighted-average exercise price, Expired
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]
Options additional disclosures
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number
Number of options, Options exercisable
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price
Weighted-average exercise price, Options exercisable
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term
Weighted-average remaining contractual life of options, outstanding
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term
Weighted-average remaining contractual life of options, exercisable
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number
Number of options, Options vested and expected to vest
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price
Weighted-average exercise price, Options vested and expected to vest
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term
Weighted-average remaining contractual life, Options vested and expected to vest
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value
Aggregate intrinsic value, options outstanding
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value
Aggregate intrinsic value, options exercisable
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum
Risk-free interest rate, minimum
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum
Risk-free interest rate, maximum
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate
Expected volatility
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate
Expected dividend yield
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term
Expected term (in years)
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Number of restricted share units
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number
Number of restricted share units, Ending balance
Number of restricted share units, Beginning balance
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period
Number of restricted share units, Granted
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period
Number of restricted share units, Vested
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period
Number of restricted share units, Forfeited
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]
Weighted-average grant date fair value
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value
Weighted-average grant date fair value, Ending balance
Weighted-average grant date fair value, Beginning balance
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value
Weighted-average grant date fair value, Granted
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value
Weighted-average grant date fair value, Vested
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value
Weighted-average grant date fair value, Forfeited
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]
Statement of Income Location, Balance [Axis]
Statement of Income Location, Balance [Domain]
Research and Development Expense [Member]
Research and Development Expenses
General and Administrative Expense [Member]
General and Administrative Expense
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share-Based Payment Arrangement, Expense
Total share-based compensation
Vesting [Axis]
Vesting [Domain]
First Anniversary [Member]
First Anniversary [Member]
First Anniversary
Second Anniversary member
Second Anniversary [Member]
Second Anniversary
Third anniversary member
Third Anniversary [Member]
Third Anniversary
Fourth Anniversary member
Fourth Anniversary [Member]
Fourth Anniversary
Over Three Years Member
Over Three Years [Member]
Over Three Years
Grantee Status [Axis]
Grantee Status [Domain]
Director [Member]
Directors
Plan Name [Axis]
Plan Name [Domain]
Information pertaining to the Company's 2018 equity incentive award plan.
2018 Incentive Award Plan
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage
Vesting percentage
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period
Vesting period
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value
Fair value of options, Vested
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value
Weighted-average grant date fair value of options granted
Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount
Total unvested options compensation expense not yet recognized
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition
Period expected to realize unrecognized compensation expense
The number of shares that have fully vested and have been deferred.
Vested shares deferred
Shares vested and deferred
Share-Based Payment Arrangement, Shares Withheld for Tax Withholding Obligation
Ordinary shares withheld for statutory tax requirements
Amount of cash outflow for realized tax benefit related to deductible compensation cost reported on the entity's tax return for equity instruments in excess of the compensation cost for those instruments recognized for financial reporting purposes.
Excess Tax Benefit from Share-based Compensation, Operating Activities1
Excess tax benefits in cash flows from operations
Amount of cash inflow from realized tax benefit related to deductible compensation cost reported on the entity's tax return for equity instruments in excess of the compensation cost for those instruments recognized for financial reporting purposes.
Excess Tax Benefit from Share-based Compensation, Financing Activities1
Excess tax benefits in cash flows from financing activities
Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount
Total compensation expense not yet recognized relating to unvested RSUs
Share Price
Common stock share price
Stock, Class of Stock [Table]
Information pertaining to BofA Securities, Inc.
Bank of America Securities, Inc. [Member]
B of A Securities, Inc.
Information pertaining to the at-the-market sales agreement to sell shares of the Company's common stock.
Sales Agreement [Member]
At-The-Market Sales Agreement
Sale of Stock [Axis]
Sale of Stock [Domain]
It represents the information pertaining to the ATM offering.
At-the-market Offering
Public Offering
Represents the member information pertaining to public offering.
Public Offering
Share Repurchase Program [Axis]
Share Repurchase Program [Domain]
Represents the information pertaining to share repurchases agreement with Perceptive Life Sciences Master Fund, Ltd.
Share Repurchase Agreement with Perceptive Life Sciences Master Fund, Ltd [Member]
Perceptive Life Sciences Master Fund, Ltd.
Class of Stock [Line Items]
Sale of Stock, Consideration Received Per Transaction
Gross proceeds from sale of ordinary shares
Sale of Stock, Number of Shares Issued in Transaction
Ordinary shares issued in transaction
Shares Issued, Price Per Share
Purchase price per share
Net Proceeds From Issuance Of Common Stock
Net Proceeds From Issuance Of Common Stock
Net proceeds from issuance of common stock, net
Share Repurchase Program, Authorized, Number of Shares
Number of shares repurchased
Share Repurchase Program, Authorized, Amount
Aggregate purchase price
Net Income (Loss) Available to Common Stockholders, Basic
Net income attributable to ordinary shareholders (numerator) - Basic
Net Income (Loss) Available to Common Stockholders, Diluted
Net income attributable to ordinary shareholders (numerator) - Diluted
Weighted Average Number of Shares Outstanding, Diluted, Adjustment [Abstract]
Dilutive effect of:
Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of stock options using the treasury stock method.
Incremental Common Shares Attributable to Dilutive Effect of Stock Options
Share options
Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of restricted stock units using the treasury stock method.
Incremental Common Shares Attributable to Dilutive Restricted Stock Units
Restricted share units
Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants
Warrants
Antidilutive Security, Excluded EPS Calculation [Table]
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]
Antidilutive Securities [Axis]
Antidilutive Securities, Name [Domain]
Warrant [Member]
Warrants
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount
Anti-dilutive securities excluded from EPS
Amount of outstanding accounts receivable recognized as part of consideration transferred in asset acquisition.
Asset Acquisition, Consideration Transferred, Accounts Receivable
Asset acquisition, consideration transferred, accounts receivable
Contract with Customer, Liability, Revenue Recognized
Deferred revenue recognized
Deferred revenue recognized
Amount of service revenue recognized based on cumulative progress.
Service Revenue Based On Cumulative Progress
Service revenue based on cumulative progress
Revenue, Remaining Performance Obligation, Amount
Remaining deferred revenue
Contract with Customer, Liability
Deferred revenue at the end
Deferred revenue at the beginning
The amount of milestone payments collected or invoiced, categorized as other.
Contract with Customer, Liability, Other Amounts Collected or Invoiced
Other amounts collected or invoiced
Represents information pertaining to Hologen Collaboration Agreement.
Hologen Collaboration Agreement [Member]
Hologen collaboration agreement
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]
Amount of revenue that was invoiced.
Revenue Recognized, Invoiced Amount
Revenue recognized invoiced amount
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period
Revenue recognized period
Contract with Customer, Refund Liability
Refund liability
Amount of increase in obligation to transfer good or service to customer for which consideration from customer has been received or is due, upon initial recognition.
Contract with Customer, Liability, Initial Recognition
Initial recognition upon execution of the Hologen Collaboration Agreement
Amount of revenue recognized that was from current period increase in the balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.
Revenue Recognized From Current Period Increase In Contract Liability
Information pertaining to Perceptive Advisors, LLC.
Perceptive Advisors, LLC
Information pertaining to the financing agreement with Perceptive Advisors, LLC.
Secured Financing Agreement
Notes Purchase Agreement
Credit Facility [Axis]
Credit Facility [Domain]
Term loans granted under the Company's financing agreement.
Term Loan
Debt Instrument [Axis]
Debt Instrument, Name [Domain]
Secured Debt [Member]
Secured Debt
Lender Name [Axis]
Line of Credit Facility, Lender [Domain]
Information pertaining to the financing agreement with Perceptive Credit Holdings..
Perceptive Credit Holdings
Portion of the principal amount, agreed to redeem.
Debt Instrument, Principal Amount, Amount to Redeem
Portion of the principal amount, agreed to redeem
Gain (Loss) on Extinguishment of Debt
Loss on extinguishment
Class of Warrant or Right, Exercise Price of Warrants or Rights
Warrant exercise price
Lessee, Lease, Description [Table]
Lessee, Lease, Description [Line Items]
Lease Maturity Term
Lease Maturity Term
Lease term
Operating Lease, Expense
Operating lease rent expenses
The number new leases recognized during the period.
Operating Lease Number New Leases Recognized
New leases recognized during period
Finance Lease, Right-of-Use Asset, Amortization
Amortization of right-of-use assets
Finance Lease, Interest Expense
Interest on lease liabilities
Variable Lease, Cost
Total finance lease cost
Operating Lease, Cost
Operating lease cost
Short-Term Lease, Cost
Short-term lease cost
Lease, Cost
Total lease cost
Operating Lease [Abstract]
Operating Lease [Abstract]
Operating leases
Operating Lease, Liability
Capitalized lease obligations
Operating lease liability
Finance Lease [Abstract]
Finance Lease [Abstract]
Finance leases
Finance Lease, Liability
Capitalized lease obligations
Finance lease liability
Weighted Average Remaining Lease Term [Abstract]
Weighted Average Remaining Lease Term [Abstract]
Weighted-average remaining lease term
Operating Lease, Weighted Average Remaining Lease Term
Operating leases
Finance Lease, Weighted Average Remaining Lease Term
Finance leases
Weighted Average Discount Rate [Abstract]
Weighted Average Discount Rate [Abstract]
Weighted-average discount rate
Operating Lease, Weighted Average Discount Rate, Percent
Operating leases
Finance Lease, Weighted Average Discount Rate, Percent
Finance leases
Cash paid for amounts included in measurement of lease liabilities [Abstract]
Cash Paid For Amounts Included In Measurement Of Lease Liabilities [Abstract]
Cash paid for amounts included in the measurement of lease liabilities
Operating Lease, Payments
Operating cash flows from operating leases
Amount of cash outflow from finance lease.
Finance Lease Payments
Financing cash flows from finance leases
Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]
Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year
2026
Lessee, Operating Lease, Liability, to be Paid, Year One
2027
Lessee, Operating Lease, Liability, to be Paid, Year Two
2028
Lessee, Operating Lease, Liability, to be Paid, Year Three
2029
Lessee, Operating Lease, Liability, to be Paid, Year Four
2030
Amount of lessee's undiscounted obligation for lease payment for operating lease due after fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).
Lessee Operating Lease Liability Payments Due After Year Four
Thereafter
Lessee, Operating Lease, Liability, to be Paid
Total undiscounted lease payments
Lessee, Operating Lease, Liability, Undiscounted Excess Amount
Less: Imputed interest
Finance Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]
Finance Lease, Liability, to be Paid, Remainder of Fiscal Year
2026
Finance Lease, Liability, to be Paid, Year One
2027
Finance Lease, Liability, to be Paid, Year Two
2028
Finance Lease, Liability, to be Paid, Year Three
2029
Finance Lease, Liability, to be Paid
Total undiscounted lease payments
Finance Lease, Liability, Undiscounted Excess Amount
Less: Imputed interest
Line of Credit Facility [Table]
Scenario [Axis]
Scenario [Domain]
Information related to warrants to buy common shares with various exercise prices.
Exercise Price - Scenario I
Information related to warrants to buy common shares with various exercise prices.
Exercise Price - Scenario II
Line of Credit Facility [Line Items]
Debt Instrument, Face Amount
Initial face amount
Debt Instrument, Interest Rate, Stated Percentage
Stated interest rate
Period of time between changes in the offered SOFR rate, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
Secured Overnight Financing Rate, Adjustment Term
SOFR adjustment term
Debt Instrument, Variable Interest Rate, Type [Extensible Enumeration]
Floor percentage for basis points added to the reference rate to compute the variable rate on the debt instrument.
Basis Spread on Variable Rate Floor
Floor percentage
Debt Instrument, Interest Rate, Effective Percentage
effective interest rate
Amount of fees, penalties, premiums, or similar charges incurred or paid as a result of the early redemption, prepayment, repurchase, or extinguishment of a debt instrument before its scheduled maturity date of the debt instrument..
Debt Instrument, Early Redemption Fee
Early redemption fee
Interest Expense, Debt
Interest expense on debt
Debt Instrument, Unamortized Discount
Unamortized debt discount
Class of Warrant or Right, Number of Securities Called by Warrants or Rights
Shares available through warrants
Represents information relating to senior secured royalty notes ("Royalty Notes").
Senior Secured Royalty Notes [Member]
Senior secured royalty notes
Represents the funding tranche related to the Second Purchase under the royalty note purchase agreement.
Second Purchase Under Royalty Note Purchase Agreement [Member]
Second purchase under royalty note purchase agreement
Represents the funding tranche related to the third purchase under the royalty note purchase agreement.
Third Purchase Under Royalty Note Purchase Agreement [Member]
Third purchase under royalty note purchase agreement
Represents information relating to funding tranche to be received upon approval of U.S. Food And Drug Administration or European Medicines Agency for bota-vec under the royalty note purchase agreement.
Upon Approval Of U.S. Food And Drug Administration or European Medicines Agency For Bota-vec [Member]
Upon approval of U.S. Food and drug administration or European medicines agency for bota-vec
Represents information relating to funding tranche to be received upon approval of U.S. Food And Drug Administration for AAV-hAQP1 under the royalty note purchase agreement.
Upon Approval Of U.S. Food And Drug Administration For AAV-hAQP1 [Member]
Upon approval of U.S. Food and drug administration for aav-haqp1
Represents information related to the additional optional funding tranche available under the Royalty Note Purchase Agreement prior to December 31, 2028.
Additional Optional Financing Before December 31, 2028 [Member]
Additional optional financing before December 31, 2028
Information pertaining to the securities purchase agreement agreement with JJDC, the investment arm of Johnson & Johnson and owner of Janssen Pharmaceuticals.
Securities Purchase Agreement [Member]
Securities Purchase Agreement
Amount of capital funding commitment provided from investors under the Royalty Note Purchase Agreement, subject to specified conditions and milestones.
Debt Instrument, Funding Commitment, Amount
Aggregate value
Represents the percentage of royalty on global net sales payable to Purchasers under a royalty-based financing arrangement.
Royalty Percentage on Global Net Sales
Royalty percentage on global net sales
Represents the aggregate of Royalty Note purchase amount that must be reached before the royalty percentage payable on global net sales becomes subject to pro rata increases for subsequent purchases under the Royalty Note Purchase Agreement.
Royalty Percentage Adjustment, Funding Threshold Amount
Aggregate purchase amount
Represents the percentage of the Total Funded Amount that the Purchasers are required to recover through Revenue Payments, milestone payments, and voluntary repurchase amounts as of the Test Date under the Royalty Note Purchase Agreement.
Total Funded Amount, Recovery Percentage
Total funded amount recovery percentage
Represents the number of trading days used to calculate the volume-weighted average price per ordinary share for purposes of determining the purchase price under the Securities Purchase Agreement.
Volume-Weighted Average Price, Measurement Period
Weighted average price days
Represents the maximum aggregate amount of ordinary shares that may be purchased by all Purchasers pursuant to the Right and Offering Participation provisions under the Securities Purchase Agreement.
Maximum Aggregate Right and Offering Participation Amount
Maximum aggregate right and offering participation amount
Loss Contingency, Damages Sought, Value
Total potential benefit associated with the filed claims
Rule 10b5-1 Arrangement Modified [Flag]
Rule 10b5-1 Arrangement Modified [Flag]
Rule 10b5-1 Arrangement Modified
Non Rule 10b5-1 Arrangement Modified [Flag]
Non Rule 10b5-1 Arrangement Modified [Flag]
Non-Rule 10b5-1 Arrangement Modified